Advertisement
Advertisement

CUE

CUE logo

Cue Biopharma, Inc.

0.77
USD
-0.01
-1.28%
Apr 17, 15:59 UTC -4
Closed
exchange

After-Market

0.74

-0.02
-3.12%

Cue Biopharma, Inc. Profile

About

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

Info & Links

CEO

Daniel R. Passeri

Headquarters

40 GUEST STREET
BOSTON, MA 02135, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.cuebiopharma.com

Auditor

RSM US LLP

Share holders

85

Employees

41

Cue Biopharma, Inc. Statistics

Valuation Measures

Market Capitalization2

46.06M

Enterprise Value

27.93M

Enterprise Value/EBITDA(ttm)

-0.68

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

9.11

Price to Book(mrq)

3.25

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-468.02%

Profit Margin(ttm)

-490.97%

Return on Equity(ttm)

-156.38%

Return on Invested Capital(ttm)

-166.35%

Return on Assets(ttm)

-88.07%

Income Statement

Revenue(ttm)

9.29M

Revenue Per Share(ttm)

0.15

Gross Profit(ttm)

9.29M

EBITDA(ttm)3

-41.07M

Net Income Available to Common(ttm)

-40.67M

Diluted EPS(ttm)

-0.90

Share Statistics

Beta (5Y Monthly)

1.66

52-Week Change

-52.82%

S&P 500 52-Week Change

6.35%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

61.82M

Dividend Yield

0.00%

Float4

55.58M

% Held by Insiders

12.26%

% Held by Institutions

35.04%

Balance Sheet

Total Cash(mrq)

23.39M

Total Cash Per Share(mrq)

0.38

Total Debt(mrq)

4.33M

Total Debt/Equity(mrq)

24.76%

Current Ratio(mrq)

1.84%

Quick Ratio(mrq)

2.22%

Book Value Per Share(mrq)

0.28

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.65

Free Cash Flow(ytd)

-36.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement